Stempoint Capital’s Sutro Biopharma STRO Stock Holding History

Stempoint Capital’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,295	Closed	-$580K	–	110
2026 Q1	$580K	Buy	+23,295	New	+$421K	0.11%	69

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Stempoint Capital's STRO Position: Q2 2026 in Review

Stempoint Capital sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 23,295 shares — an estimated $580K sold.

Stempoint Capital first reported a position in STRO in Q1 2026 and held it in 1 quarter. The position peaked at $580K in Q1 2026. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Stempoint Capital reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
Stempoint Capital sold 23,295 Sutro Biopharma shares in Q2 2026, an estimated $580K.
Stempoint Capital first reported a position in Sutro Biopharma in Q1 2026 and held it in 1 quarter.
Stempoint Capital's Sutro Biopharma position peaked at $580K in Q1 2026.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.